Form 4: Tenax Therapeutics Director Michael H. Davidson Acquires Shares and Warrants in Private Placement

Director Michael H. Davidson purchased shares, pre-funded warrants, and warrants of Tenax Therapeutics in a private placement on August 8, 2024.

Summary

• Michael H. Davidson, a director of Tenax Therapeutics, acquired 2,500 shares of common stock on August 8, 2024, as part of a private placement.
• He also purchased 47,500 pre-funded warrants and 25,000 warrants to purchase shares of common stock.
• The purchase was made pursuant to a Securities Purchase Agreement dated August 6, 2024.
• The price for each share and accompanying warrant was $3.00, while the price for each pre-funded warrant and accompanying warrant was $2.99.
• The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study; (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.
• Davidson also owns stock options to buy 4 shares at $992 and 4 shares at $3,200.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's purchase of shares and warrants, indicating confidence in the company's future. However, the details of the private placement and warrant terms need to be carefully considered.

Positives

• Director's purchase of shares and warrants signals confidence in the company.

Future Outlook

The warrant expiration is tied to the announcement of topline data from the Phase 3 LEVEL Study, suggesting the timing of this announcement is a key event to watch.

Industry Context

Insider buying is often seen as a positive signal, suggesting that those with the most knowledge of the company's prospects are optimistic about its future. However, the specific terms of the private placement and warrants should be considered in the context of the company's overall financial strategy.

Comparison to Industry Standards

• It's difficult to compare this specific transaction to industry standards without knowing the specifics of other similar private placements in the biotech industry.
• However, insider buying is generally viewed positively, especially when it involves significant amounts.
• The warrant terms, particularly the expiration date tied to the Phase 3 study results, are relatively common in biotech financings.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal.
• The private placement could potentially dilute existing shareholders, depending on the number of shares issued.
• The success of the Phase 3 LEVEL Study is crucial for the company's future and will impact all stakeholders.

Next Steps

• Monitor the announcement of topline data from the Phase 3 LEVEL Study, as this will impact the warrant expiration date.
• Track any further insider transactions.

Key Dates